UBS Group
KROS icon

UBS Group’s Keros Therapeutics KROS Stock Holding History

UBS Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Sell
137,987
-7,586
-5% -$84.5K ﹤0.01% 5384
2026
Q1 		$1.61M Buy
145,573
+48,489
+50% +$749K ﹤0.01% 5165
2025
Q4 		$1.98M Sell
97,084
-6,780
-7% -$119K ﹤0.01% 4994
2025
Q3 		$1.64M Buy
103,864
+1,091
+1% +$16.1K ﹤0.01% 5145
2025
Q2 		$1.37M Buy
102,773
+10,344
+11% +$140K ﹤0.01% 5166
2025
Q1 		$942K Sell
92,429
-82,512
-47% -$958K ﹤0.01% 5327
2024
Q4 		$2.77M Buy
174,941
+119,034
+213% +$6.19M ﹤0.01% 4408
2024
Q3 		$3.25M Sell
55,907
-9,648
-15% -$476K ﹤0.01% 3511
2024
Q2 		$3M Sell
65,555
-58,630
-47% -$3.15M ﹤0.01% 3350
2024
Q1 		$8.22M Sell
124,185
-57,200
-32% -$3.39M ﹤0.01% 2451
2023
Q4 		$7.21M Buy
181,385
+174,798
+2,654% +$5.48M ﹤0.01% 2381
2023
Q3 		$210K Sell
6,587
-23,129
-78% -$863K ﹤0.01% 5337
2023
Q2 		$1.19M Sell
29,716
-3,335
-10% -$146K ﹤0.01% 4069
2023
Q1 		$1.41M Sell
33,051
-16,128
-33% -$815K ﹤0.01% 3781
2022
Q4 		$2.36M Sell
49,179
-114,060
-70% -$5.33M ﹤0.01% 3235
2022
Q3 		$6.14M Sell
163,239
-33,676
-17% -$1.17M ﹤0.01% 2173
2022
Q2 		$5.44M Sell
196,915
-2,768
-1% -$121K ﹤0.01% 2304
2022
Q1 		$10.9M Buy
199,683
+44,068
+28% +$2.26M ﹤0.01% 1878
2021
Q4 		$9.11M Buy
155,615
+25,833
+20% +$1.29M ﹤0.01% 2226
2021
Q3 		$5.13M Buy
129,782
+128,362
+9,040% +$4.57M ﹤0.01% 2642
2021
Q2 		$60K Sell
1,420
-14,147
-91% -$766K ﹤0.01% 6271
2021
Q1 		$958K Buy
15,567
+15,318
+6,152% +$970K ﹤0.01% 4303
2020
Q4 		$18K Buy
+249
New +$15.7K ﹤0.01% 7013
2020
Q3 		– Sell
-2,207
Closed -$83K – 8227
2020
Q2 		$83K Buy
+2,207
New +$68K ﹤0.01% 5443

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group's KROS Position: Q2 2026 in Review

UBS Group reduced its Keros Therapeutics (KROS) stake by 5.2% in Q2 2026, selling an estimated $84.5K and leaving 137,987 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #5384.

UBS Group first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $10.9M in Q1 2022. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • UBS Group held 137,987 shares of Keros Therapeutics worth $1.48M as of Q2 2026.
  • UBS Group sold 7,586 Keros Therapeutics shares in Q2 2026, an estimated $84.5K.
  • Keros Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5384 holding.
  • UBS Group first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • UBS Group's Keros Therapeutics position peaked at $10.9M in Q1 2022.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.